ENHERTU demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival compared to T-DM1 in patients with HER2-positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE